IRIS
ANDREONI, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 82.674
AS - Asia 12.319
EU - Europa 10.741
SA - Sud America 1.818
AF - Africa 272
OC - Oceania 53
Continente sconosciuto - Info sul continente non disponibili 31
Totale 107.908
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 82.228
SG - Singapore 5.486
IT - Italia 2.300
CN - Cina 2.197
BR - Brasile 1.502
RU - Federazione Russa 1.432
DE - Germania 1.405
HK - Hong Kong 1.115
UA - Ucraina 1.036
IE - Irlanda 1.035
KR - Corea 943
VN - Vietnam 908
SE - Svezia 720
FR - Francia 696
GB - Regno Unito 594
BD - Bangladesh 507
FI - Finlandia 490
PL - Polonia 341
JP - Giappone 304
CA - Canada 250
IN - India 215
NL - Olanda 175
ZA - Sudafrica 106
AR - Argentina 105
MX - Messico 104
ID - Indonesia 98
AT - Austria 97
TR - Turchia 91
BE - Belgio 88
ES - Italia 79
IQ - Iraq 75
CZ - Repubblica Ceca 65
PK - Pakistan 51
AU - Australia 49
EC - Ecuador 48
CO - Colombia 44
PH - Filippine 42
CL - Cile 39
VE - Venezuela 33
KG - Kirghizistan 31
MA - Marocco 31
SA - Arabia Saudita 26
UZ - Uzbekistan 25
CH - Svizzera 24
AE - Emirati Arabi Uniti 23
JM - Giamaica 23
JO - Giordania 23
EU - Europa 21
IR - Iran 21
LT - Lituania 21
TN - Tunisia 20
IL - Israele 19
PY - Paraguay 19
GR - Grecia 18
KE - Kenya 18
RO - Romania 18
EG - Egitto 17
MY - Malesia 17
KZ - Kazakistan 15
DZ - Algeria 14
TW - Taiwan 14
AL - Albania 12
CR - Costa Rica 12
ET - Etiopia 12
PE - Perù 12
CM - Camerun 11
NP - Nepal 11
HR - Croazia 10
PT - Portogallo 10
TH - Thailandia 10
DK - Danimarca 9
HN - Honduras 9
UY - Uruguay 9
A2 - ???statistics.table.value.countryCode.A2??? 8
OM - Oman 8
TT - Trinidad e Tobago 8
BA - Bosnia-Erzegovina 7
NO - Norvegia 7
AO - Angola 6
AZ - Azerbaigian 6
BG - Bulgaria 6
BH - Bahrain 6
HU - Ungheria 6
LV - Lettonia 6
NG - Nigeria 6
RS - Serbia 6
SI - Slovenia 6
DO - Repubblica Dominicana 5
LB - Libano 5
PA - Panama 5
SC - Seychelles 5
BO - Bolivia 4
GH - Ghana 4
GT - Guatemala 4
MK - Macedonia 4
NI - Nicaragua 4
NZ - Nuova Zelanda 4
PR - Porto Rico 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
Totale 107.826
Salva come PNG Salva come JPEG
Città #
Woodbridge 21.632
Wilmington 21.426
Houston 15.553
Singapore 3.205
Fairfield 2.567
Ashburn 1.925
Chandler 1.860
Ann Arbor 1.816
San Jose 1.532
Hong Kong 1.095
Seattle 1.079
Beijing 880
Cambridge 870
Dublin 869
Jacksonville 815
Rome 742
New York 673
Medford 649
Dearborn 568
Council Bluffs 537
Santa Clara 520
The Dalles 466
Los Angeles 462
Lawrence 304
Ho Chi Minh City 281
Tokyo 274
Helsinki 256
Kraków 254
Moscow 232
Hanoi 228
Milan 227
Buffalo 216
Lauterbourg 211
Dallas 210
San Diego 202
Munich 161
São Paulo 161
Menlo Park 158
Orem 145
Zhengzhou 127
Nuremberg 117
London 111
Mülheim 97
Boardman 95
Chicago 90
Phoenix 88
Brussels 87
North Bergen 81
Montreal 78
Redondo Beach 78
Chennai 74
Frankfurt am Main 71
Toronto 69
Jakarta 68
Atlanta 63
Warsaw 63
Denver 61
Nanjing 59
Amsterdam 58
Brooklyn 57
Johannesburg 57
Palo Alto 57
Guangzhou 51
Shanghai 51
Falls Church 50
San Francisco 50
Stockholm 49
Redwood City 48
Rio de Janeiro 48
Manchester 47
Naples 46
Norwalk 45
Verona 44
Dong Ket 43
Hefei 43
Hangzhou 42
San Mateo 41
Columbus 39
Poplar 38
Seoul 38
Belo Horizonte 37
Da Nang 37
Mountain View 37
Vienna 37
Brno 36
Boston 35
Mexico City 33
Ankara 32
Kunming 32
Baghdad 30
Creede 29
Curitiba 29
Haiphong 29
Bari 28
Lappeenranta 28
University Park 28
Mumbai 27
Salt Lake City 27
Paris 26
Charlotte 23
Totale 88.500
Salva come PNG Salva come JPEG
Nome #
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 579
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 577
Microbiologic characteristics and predictors of mortality in bloodstream infections in intensive care unit patients: A 1-year, large, prospective surveillance study in 5 Italian hospitals 541
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 534
18-Fluoro-2-deoxyglucose positron emission tomography-computed tomography: an additional tool in the diagnosis of prosthetic valve endocarditis. 523
Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals 519
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 515
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 510
Human herpesvirus-8 infection in pregnancy and labor: Lack of evidence of vertical transmission 504
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 492
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 490
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 490
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 486
Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy 484
A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects. 484
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 482
Prognostic factors of long-term CD4+ count-guided interruption of antiretroviral treatment 481
Infection with human herpesvirus type 8 and Kaposi's sarcoma in a central Italian area formerly endemic for malaria 481
Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens 477
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 477
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 476
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 475
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 472
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (< 400 HIV-RNA cp/ml) during different antiretroviral regimens 467
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 467
Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing 465
A fatal case of invasive fungal sinusitis by Scopulariopsis acremonium in a bone marrow transplant recipient 465
Efficient and reproducible new semimicromethod for the detection and titration of HIV in human plasma 464
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 463
HIV plasma viremia in 22 seropositive subjects [VALUTAZIONE DELLA VIREMIA PLASMATICA DA HIV IN 22 SOGGETTI SIERO-POSITIVI] 462
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 462
Multidrug resistance after lamivudine therapy for chronic hepatitis B 462
Dysplasia of Granulocytes in a Patient with HPV Disease, Recurrent Infections, and B Lymphopenia: A Novel Variant of WHIM Syndrome? 459
Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy. 453
Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy 452
Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART 451
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 448
Neutralizing antibodies against autologous human immunodeficiency virus type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment 447
Reduction of IFN-gamma and IL-2 production by peripheral lymphocytes of HIV-exposed seronegative subjects 446
Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations 445
Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy 445
A case of rhabdomiolysis associated with raltegravir use 445
High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis 444
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 444
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 444
High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. 444
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 443
HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity 443
Cortical sources of resting state electroencephalographic rhythms probe brain function in naïve HIV individuals 442
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 441
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 438
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 438
Human herpesvirus 8 and human herpesvirus 2 infections in prison population 437
ellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy. 437
Viral growth assay to evaluate the replicative capacity of HIV-1 isolates 435
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 434
Correlates of HIV, HBV, and HCV infections in a prison inmate population: Results from a multicentre study in Italy 431
Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (invirase) treatment 431
Dapsone hypersensitivity syndrome complicated by Scedosporium apiospermum pneumonia in an immunocompetent patient. 431
Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: impact on susceptibility to first-line strategies including Integrase strand-transfer inhibitors 431
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 430
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 430
Five human immunodeficiency virus type 1 phenotypic variants with different MT-2 cell tropisms correlate with prognostic markers of disease 430
Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy 429
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 429
Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapy 429
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 429
Complication of nasal piercing by Staphylococcus aureus endocarditis: a case report and a review of literature. 428
Infection with human herpesvirus-8 and its correlation with hepatitis B virus and hepatitis C virus markers among rural populations in Cambodia 427
Prevalence of HHV-8 infection in Albanian adults and association with HBV and HCV 426
Plasma Viremia Titration and RNA Quantitation in ICD-p24 Negative HIV Type-1-Infected Patients 426
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 424
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 423
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 423
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 421
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 421
Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: A cross-sectional evaluation 420
Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon 420
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages 419
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 419
Prevalence trend and correlates of HHV-8 infection in HIV-infected patients 418
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors 418
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation 418
HBV, HCV, HDV AND HEV COINFECTIONS IN A COHORT OF HIV POSITIVE PATIENTS IN CAMEROON 418
Primary human herpesvirus 8 infection in immunocompetent children. 417
Human herpesvirus 8 cytoviraemia rebound in a patient with Kaposi's sarcoma after a short interruption of efficient antiretroviral therapy. 417
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 417
Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. 416
KSHV DNA viremia correlates with low CD4+ cell count in Italian males at the time of diagnosis of HIV infection 415
HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy 415
Once-a-day (QD) vs. Twice-daily (BID) Nevirapine as Simplification in PI-Treated Patients after 2 mos. of BID Induction 414
Biomarkers of monitoring and functional reserve of physiological systems over time in HIV: expert opinions for effective secondary prevention 414
Infection with human herpesvirus type 8 and human T-cell leukaemia virus type 1 among individuals participating in a case-control study in Havana City, Cuba 413
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 408
Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals 407
Dual mixed (but not X4) tropic-HIV-1 isolates can replicate in human primary macrophages and are inhibited by CCR5- inhibitors 407
Non-B HIV type 1 subtypes: Replicative capacity and response to antiretroviral therapy 406
High rate of HIV isolation from plasma of asymptomatic patients through polyethylene glycol (PEG) treatment 405
Development of cellulitis caused by Aeromonas hydrophila in allogeneic hematopoietic transplantation: a case report. 405
Impact of pre-therapy viral load on virological response to modern first-line HAART 404
Totale 44.860
Salva come PNG Salva come JPEG
Categoria #
all - tutte 288.170
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 288.170
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.981 183 312 229 271 171 448 223 213 466 307 243 915
2022/20234.898 479 400 301 641 413 1.043 371 348 460 36 270 136
2023/20242.072 261 75 158 110 162 446 102 148 54 144 28 384
2024/20259.077 321 1.861 918 646 277 584 878 551 918 907 643 573
2025/202615.627 1.195 648 1.597 1.399 1.469 676 2.111 1.823 1.917 1.289 829 674
2026/2027673 673 0 0 0 0 0 0 0 0 0 0 0
Totale 109.352